Acceptance and results of therapy with omalizumab in real world Kerala setting: reports from the ARTWORK study, Kerala, South India. (2nd September 2022)

• Record Type: Journal Article
• Authors: Venkitakrishnan, Rajesh; Cleetus, Melcy; Augustine, Jolsana; Ramachandran, Divya; John, Susan; Vijay, Anand; Nirmal, Aparna S.; Sasi, Anju; Kuriachen, Elda
• Is Part Of: Journal of asthma. Volume 59:Number 9(2022)
• Page Start: 1831
• Page End: 1838
• Publication Date: 2022-09-02
• Subjects: Severe asthma -- omalizumab -- anti IgE therapy -- patient preference; Asthma -- Periodicals; 616.238005
• DOI: 10.1080/02770903.2021.1968425
• Languages: English
• ISSNs: 0277-0903

Abstract

Abstract: Objective: Despite the availability of effective medications, only a minority of asthma patients achieve guideline defined asthma control. Treatment success depends on patient concurrence to the prescribed drug and adherence to treatment. It is therefore crucial to identify the patient preferences as well as attitudes towards asthma medications. Omalizumab is recommended as a preferred option in step 5 of asthma therapy. There have been few studies to address patient perspectives on omalizumab therapy in India. Methods: This was a retrospective study. Patients with inadequate asthma control were considered for the study. Systematic evaluation was done to identify and correct modifiable factors that can worsen asthma control. Patients with persisting poor asthma control who were deemed suitable to receive this agent were evaluated with their attitudes toward acceptance or refusal and the reasons for opting out were noted. The patients who received omalizumab were followed up to determine the results of treatment and duration of adherence to therapy. Results: Thirty-five patients out of 51 patients chose to avoid this drug. The reasons for opting out included erroneous perception of optimal asthma control, cost of therapy, and concern about adverse effects. Patients took omalizumab for a median duration of 6 months. Improved asthma control and decreased frequency of exacerbation was noted in all patients which persisted during the 6-month follow-up. Conclusions: The majority of patients needing step 5 therapy opt out of omalizumab. Cost of drug, duration of therapy and erroneous perception of good asthma control account for refusing treatment. Omalizumab affords excellent clinical benefits to patients who receive it, and the benefits extend beyond the duration of therapy.